Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Amir Z Munir *Section of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0009-0009-3512-5851
Alan Gutierrez *Section of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0000-0001-9129-243X
Cade J KrawiecSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0009-0007-5127-6938
Priyanka ManandharSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0000-0003-2868-5286
Anya C ShyaniSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).
Pan MaCardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, MO (P. Ma, K.J.L.).ORCID 0000-0002-0815-849X
Paul GougisDepartment of Medical Oncology, Assistance Publique - Hôpitaux de Paris, Institut Universitaire de Cancérologie, INSERM U1136, CLIP2 Galilée (P.G.).ORCID 0000-0003-3064-7043
Richard A BaylisSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0000-0001-7040-7920
Lifei HouDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, MA (L.H.), Harvard Medical School, Boston, MA.ORCID 0000-0001-8975-7795
Eileen Remold-O'DonnellEdelweiss Immune Inc, Cambridge, MA (E.R.-O.).
Justin M BalkoDepartment of Medicine, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN (J.M.B.).ORCID 0000-0002-4263-5974
Joe-Elie SalemClinical Investigation Center Paris-Est, CIC-1901/INSERM, Department of Pharmacology (J.-E.S.).ORCID 0000-0002-0331-3307
Kory J LavineCardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, MO (P. Ma, K.J.L.).ORCID 0000-0003-1948-9945
Andrew H LichtmanDepartment of Pathology, Brigham and Women's Hospital (A.H.L.), Harvard Medical School, Boston, MA.
Juan QinSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0000-0002-0821-6290
Javid J MoslehiSection of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco (A.Z.M., A.G., C.J.K., P. Manandhar, A.C.S., R.A.B., J.Q., J.J.M.).ORCID 0000-0001-5443-4312
Funding
Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1M
MULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Christine T. Pham · 2018 to 2026
$7.6M
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9M
Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · PI Kory J. Lavine · 2022 to 2026
$4.3M
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapyR01HL160688 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jelena Levi, Youngho Seo · 2022 to 2026
$3.4M
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3M
Long-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3M
Novel patient biomarkers and mechanisms of TKI associated CardiotoxicityR01HL170038 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Daniel Addison · 2023 to 2026
$2.7M
The Role of Donor Innate Immune Responses in Regulating Alloimmunity after Heart TransplantationR01HL151078 · NHLBI · WASHINGTON UNIVERSITY · PI KREISEL, DANIEL, LAVINE, KORY J. · 2020 to 2023
$2.6M
MACROPHAGE HETEROGENEITY IN HEART FAILURE PROGRESSION AND CARDIAC RECOVERYR01HL138466 · NHLBI · WASHINGTON UNIVERSITY · PI LAVINE, KORY J. · 2017 to 2021
$1.9M
MACROPHAGE ONTOGENY SHIFTS IN ISCHEMIC HEART DISEASER01HL139714 · NHLBI · WASHINGTON UNIVERSITY · PI LAVINE, KORY J. · 2018 to 2021
backgroundMyocarditis is a severe complication of immune checkpoint inhibitors (ICIs). The major risk factor for ICI myocarditis is the use of combination ICI treatment, especially when relatlimab, a novel anti-LAG-3 (lymphocyte-activation gene 3) antibody, is combined with anti-PD-1 (programmed cell death protein 1) therapy. Although pathogenic T cells are necessary for ICI myocarditis, the specific signaling and T-cell populations that drive cardiac infiltration have not been fully elucidated, especially in setting of anti-LAG-3/PD-1 treatment.
methodsWe used VigiBase, an international pharmacovigilance database, to assess the risk of myocarditis with anti-LAG-3 compared with other ICI treatment regimens. We identified a mouse model of LAG-3/PD-1-associated ICI myocarditis through genetic deletion of immune checkpoints LAG-3 and PD-1 (
resultsWe found an increased risk of myocarditis with anti-LAG-3 combination treatment clinically, confirming early clinical trial data.
conclusionsOur findings suggest that ICI myocarditis is driven by an expansion of CXCR6
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.